Icahn School of Medicine at Mount Sinai

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Icahn School of Medicine at Mount Sinai sits in the top decile of US sponsors by registered trial count (#48 of 15,742 sponsors by registered trial count).

708 total trials 163 currently recruiting 423 completed early-phase tilt top decile by trial count

Icahn School of Medicine at Mount Sinai: 708 sponsored US clinical trials, 163 recruiting.

Icahn School of Medicine at Mount Sinai sponsors 708 registered US clinical trials on ClinicalTrials.gov, 163 of them currently recruiting, and 423 completed. 88 of these trials are in Phase 3-4 (later-stage) and 138 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 7 trials.

Top-decile sponsor footprint

Icahn School of Medicine at Mount Sinai ranks in the top decile of sponsors by registered trial count (#48 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 51/100

423 of 499 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

708 total, page 3 of 15

RECRUITING

Behavioral and Cognitive Predictors of Persistent Pain and Opioid Misuse in Chronic Pain

NCT06288282

RECRUITING NA

Changes in Inhibition and Valuation After Eating

NCT05995496

RECRUITING NA

Persuasive Health Communication Intervention for HIV/HCV

NCT05968573

RECRUITING Phase 3

SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)

NCT06945315

RECRUITING

Maternal And Infant Antipsychotic Study

NCT06049953

RECRUITING NA

CTSN Embolic Protection Trial

NCT06027788

RECRUITING NA

Phase 2 - Rhythmic Light Therapy for Alzheimer's Disease Patients

NCT05016219

RECRUITING

Pregnant Women With and Without Crohns Disease to Explore the Role of Plastics and Toxins in Intestinal Inflammation

NCT06001450

RECRUITING Phase 2

Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

NCT05835466

RECRUITING NA

Telehealth Cognitive Behavioral Therapy for Youth at Risk for Psychosis

NCT05968560

RECRUITING NA

Community-based Implementation of Online EmReg

NCT05933629

RECRUITING NA

Network Neurofeedback Using 7-Tesla MRI to Reduce Rumination Levels in Depression

NCT05933148

RECRUITING NA

The Role of the Gastrointestinal-associated Lymphoid Tissue in the Cure of HIV Infection

NCT05652088

RECRUITING Phase 4

Impact of Prophylactic Ephedrine on Fetal Heart Tracing and Uterine Tetanic Contraction After CSE

NCT05873218

RECRUITING Phase 2

Pembrolizumab for Advanced NSCLC and PS 2-3

NCT05589818

RECRUITING NA

Development and Testing of a Peer-Coaching Model for the Treatment of Eating Disorders

NCT05562258

RECRUITING NA

Delivering Empowering Conversations About Obstetric Regional Anesthesia for Underserved Minorities

NCT05260242

RECRUITING NA

Imaging Coronary Microvascular Dysfunction (CMD) Study

NCT05634031

RECRUITING NA

Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials

NCT05146297

RECRUITING

Neurocognitive and Genomic Predictors of Persistent Pain and Opioid Misuse After Spine Surgery

NCT06288256

RECRUITING Phase 2

Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer

NCT05462496

RECRUITING NA

Interoceptive Exposure for Adolescents With Low Weight Eating Disorders

NCT05763849

RECRUITING Early Phase 1

Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma

NCT05188118

RECRUITING NA

The Ambient Light Multiple Myeloma Study

NCT05737732

RECRUITING Phase 1

Vancomycin Study in Multiple Sclerosis (MS)

NCT05539729

RECRUITING NA

DevRobust Treatment for Mal de Débarquement Syndrome

NCT05460520

RECRUITING NA

Efficacy of Non-invasive Vagus Nerve Stimulation for Treatment of Low Weight Eating Disorders

NCT05554172

RECRUITING NA

Effects of Stereotype Threat on Impulsivity and Its Relation to Alcohol Use in African Americans: An fMRI Study

NCT05675332

RECRUITING NA

Metabolic Diet for Relapse Prevention in Anorexia Nervosa

NCT05197309

RECRUITING

A Multi Center Study of Sexual Toxicities After Radiotherapy

NCT05394428

RECRUITING

Identification of Acute Intermittent Porphyria Modifying Genes

NCT05502133

RECRUITING NA

Transcranial Ultrasound Via Sonolucent Cranioplasty After Minimally Invasive Intracerebral Hemorrhage Evacuation

NCT05538286

RECRUITING Phase 2

The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial)

NCT05419089

RECRUITING NA

Intraventricular Catheter System for IVH

NCT05970549

RECRUITING

Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders

NCT05982925

RECRUITING NA

The Effects of Entrainment on Respiratory Stability and Cerebral Oxygenation in Preterm Infants

NCT05223192

RECRUITING NA

Screening Women With Prior HPV for Anal Neoplasia

NCT05217940

RECRUITING

Environmental Factors and Thyroid Cancer

NCT05172921

RECRUITING NA

TSCS for Acute SCI

NCT05305118

RECRUITING NA

Invasive Decoding and Stimulation of Altered Reward Computations in Depression Patients

NCT05239780

RECRUITING NA

Mammography and Breast Arterial Calcification: An Information-Sharing Trial

NCT04983875

RECRUITING Phase 1

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

NCT05095207

RECRUITING NA

Connectomic Deep Brain Stimulation for Obsessive Compulsive Disorder

NCT05160129

RECRUITING

Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors

NCT04615988

RECRUITING NA

Early Feeding After Oral Cavity Reconstruction

NCT04787939

RECRUITING

Biologics And Clinical Immunology Cohort at Sinai

NCT04784364

RECRUITING NA

Use of ReDS Technology in Patients With Acute Heart Failure

NCT04305717

RECRUITING Phase 1

Effects of Vagal Dysfunction on Gastrointestinal and Inflammatory Pathways in HIV

NCT04353778

RECRUITING Phase 3

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

NCT04045665

RECRUITING

Clinical and Basic Investigations Into Congenital Disorders of Glycosylation

NCT04199000

← Previous Page 3 of 15 Next →

Phase Distribution

PhaseTrial count
Phase 1 57
Phase 2 81
Phase 3 21
Phase 4 67

What is open in the Icahn School of Medicine at Mount Sinai pipeline

163 recruiting of 708 indexed (23% open); 423 completed (60%).

Phase mix: 88 late (III/IV) vs 138 early (I/II) (early-phase heavy).

Top condition: Prostate Cancer (7 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Icahn School of Medicine at Mount Sinai: open-pipeline peers nationwide

Peers matched on 708 registered trials and 23% open enrollment, not the therapeutic-area sidebar.

Icahn School of Medicine at Mount Sinai sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600800 5%10%15%20%25% Total trials Recruiting share Icahn School of Medicine at Mount SinaiSanofiWeill Medical College of Cornell UniversityUniversity of MiamiThe Cleveland ClinicClemson UniversityLiberating TechnologiesRahul AggarwalSequenom
Icahn School of Medicine at Mount Sinai sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Icahn School of Medicine at Mount Sinai sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 708 trials (± recruiting share)

Sponsors near 23% open enrollment (± trial volume)

What to do with this Icahn School of Medicine at Mount Sinai page

708 registered trials is a research-attention snapshot, not an endorsement of Icahn School of Medicine at Mount Sinai or any single study.

  • 163 of Icahn School of Medicine at Mount Sinai's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Prostate Cancer is the condition Icahn School of Medicine at Mount Sinai studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Icahn School of Medicine at Mount Sinai pipeline card: 708 registered trials from official public datasets.Report a data error.